Cipla Just Entered the Keytruda Biosimilar Race — But It Does Not Control the Hardest Step
Cipla has exclusive US commercial rights to QL2107, while Qilu keeps responsibility for development, registration and supply—a split that concentrates both the upside and the dependency.